progyny is the leading fertility benefits company that combines service, science, technology and data to provide fertility solutions for self-insured employers. progyny’s approach offers members a comprehensive value based treatment plan that is based on the latest medical science and technology. the benefit plans are designed to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. progyny supports all fertility solutions to include ivf, iui, embryo banking, egg freezing, adoption and surrogacy.
![Progyny logo](/files/LOGO/1551306-PGNY.png)
Company profile
Ticker
PGNY
Exchange
Website
CEO
David J. Schlanger
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Auxogyn Inc, Auxogyn, Inc.
SEC CIK
Corporate docs
IRS number
272220139
PGNY stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
29 May 24
8-K
Other Events
22 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Progyny, Inc. Announces First Quarter 2024 Results
9 May 24
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Progyny, Inc. Announces Fourth Quarter 2023 Results
27 Feb 24
Transcripts
PGNY
Earnings call transcript
2024 Q1
9 May 24
PGNY
Earnings call transcript
2023 Q4
27 Feb 24
PGNY
Earnings call transcript
2023 Q3
7 Nov 23
PGNY
Earnings call transcript
2023 Q2
3 Aug 23
PGNY
Earnings call transcript
2023 Q2
3 Aug 23
PGNY
Earnings call transcript
2023 Q1
8 May 23
PGNY
Earnings call transcript
2022 Q4
27 Feb 23
PGNY
Earnings call transcript
2022 Q3
4 Nov 22
PGNY
Earnings call transcript
2022 Q2
7 Aug 22
PGNY
Earnings call transcript
2022 Q1
6 May 22
Latest ownership filings
4
Michael E Sturmer
18 Jul 24
144
Notice of proposed sale of securities
16 Jul 24
4
Peter Anevski
2 Jul 24
4
David J Schlanger
2 Jul 24
4
Cheryl Scott
1 Jul 24
144
Notice of proposed sale of securities
28 Jun 24
4
Mark S. Livingston
5 Jun 24
4
Michael E Sturmer
5 Jun 24
4
Allison Swartz
30 May 24
4
Michael E Sturmer
30 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 114.96 mm | 114.96 mm | 114.96 mm | 114.96 mm | 114.96 mm | 114.96 mm |
Cash burn (monthly) | (no burn) | 3.36 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 13.00 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 101.96 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 30.3 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 314 |
Opened positions | 121 |
Closed positions | 44 |
Increased positions | 90 |
Reduced positions | 70 |
13F shares | Current |
---|---|
Total value | 3.28 tn |
Total shares | 104.37 mm |
Total puts | 143.30 k |
Total calls | 183.90 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 11.15 mm | $425.22 bn |
Vanguard | 8.31 mm | $317.10 bn |
TPG GP A | 6.60 mm | $251.70 bn |
Kleiner Perkins Caufield & Byers Xiii | 6.47 mm | $325.94 mm |
MKGAF Merck KGaA | 4.30 mm | $182.17 mm |
JPM JPMorgan Chase & Co. | 3.53 mm | $134.76 bn |
Clearbridge Advisors | 3.50 mm | $133.41 bn |
STT State Street | 2.90 mm | $110.60 bn |
Jennison Associates | 2.60 mm | $99.05 bn |
FMR | 2.45 mm | $93.46 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Jul 24 | Michael E Sturmer | Common Stock | Sell | Dispose S | No | Yes | 30 | 9,030 | 270.90 k | 362,583 |
1 Jul 24 | Schlanger David J | Common Stock | Payment of exercise | Dispose F | No | No | 28.61 | 2,681 | 76.70 k | 80,950 |
1 Jul 24 | Anevski Peter | Common Stock | Payment of exercise | Dispose F | No | No | 28.61 | 7,977 | 228.22 k | 239,940 |
28 Jun 24 | Scott Cheryl | Common Stock | Sell | Dispose S | No | No | 28.39 | 1,462 | 41.51 k | 10,098 |
3 Jun 24 | Michael E Sturmer | Common Stock | Payment of exercise | Dispose F | No | No | 26.95 | 448 | 12.07 k | 371,613 |
News
Forecasting The Future: 6 Analyst Projections For Progyny
16 Jul 24
JMP Securities Initiates Coverage On Progyny with Market Outperform Rating, Announces Price Target of $36
16 Jul 24
Truist Securities Maintains Buy on Progyny, Lowers Price Target to $37
17 May 24
Cantor Fitzgerald Reiterates Overweight on Progyny, Maintains $48 Price Target
16 May 24
Barclays Maintains Overweight on Progyny, Lowers Price Target to $30
13 May 24
Press releases
Progyny, Inc. Announces Details for Its Second Quarter 2024 Results Report
23 Jul 24
Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of Growth
11 Jun 24
Progyny, Inc. to Present at Jefferies Global Healthcare Conference
4 Jun 24
Progyny, Inc. Announces Additional Share Repurchase Program
22 May 24
Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024
14 May 24